Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 33Multiple Myeloma 30Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Graft vs Host Disease 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma 24Leukemia 24Hematologic Neoplasms 20Neoplasms 18Lymphoma, Mantle-Cell 18Sarcoma 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 17Tuberous Sclerosis 15Myeloproliferative Disorders 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Burkitt Lymphoma 14Waldenstrom Macroglobulinemia 13Lymphoma, B-Cell, Marginal Zone 13Recurrence 12Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Prostatic Neoplasms 11Primary Myelofibrosis 11Melanoma 11Leukemia, Myelomonocytic, Chronic 11

Interventions

Cannabidiol 2Timolol 1Sirolimus 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sturge-Weber Syndrome × Sirolimus × Clear all
NCT03047980 2021-11-01

Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2/3 Completed
10 enrolled 11 charts

Sturge-Weber Syndrome, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡